Ann: Successful Completion of DSMB Review of Phase 3 FSGS Trial, page-24

From a licensing opportunity view, the company ticks all the boxes....

IP, multi billion $ market, no approved therapies yet,
potential of being first to second in market, Orphan designation, patient impact etc...So this is the good part.

Scary part now:

there is absolutely nothing that suggest there is any interest from any partner. Biotech is a small world and if there were multiple partner's interested, you would have seen one jumping the gun as no one wants to miss out.

The Travere deal is great from a risk benefit ratio... it's total deal of 865m of which only 55m is upfront while another 150m is paid at milestones of trial progress while the rest is all linked to future sales I.e. no sales, no royalty. 200m is pocket change for these big Pharma or even small Pharma.... so risk benefit is very attractive but still no one has put anything concrete on the table.

My view is that is it to do with the fact that we only have 7 or 8 patient data from our P2 trial. I know it's Orphan drug but May be it's still too few patients for them to make an assessment of clinical data. In that regard, it makes sense for them to wait for 1st interim results and make a move if it turns out to be positive.

But on the outside, it looks like that Dimerix team hasn't been able to convince those BP from conferences that they have a sure shot winner or something worth taking a risk at this stage and it does put the risk benefit ration for us in balance, I.e. it can go anyway. (I hope to be proven wrong).

By the way, in event of a successful interim results and if the deal is signed, let's hold the team accountable to deliver similar value or there abouts as Vifor paid Travere which is in region of 850m USD ex US, or 2bn including US (US sales will account for more than 50% of total sales).... reason I highlighted this is coz there are few SH who gets excited the movement we hit close to 20c... that's what low share price does to expectations lol...